Mortality Rates and Causes of Death in a Cohort of HIV-Infected and Uninfected Women, 1993-1999

Journal of Urban Health

Volumn 80, Issue 4, 2003, Pages 676-688

  Smith, Dawn K ^a   Gardner, Lytt I ^a   Phelps, Ruby ^a   Hamburger, Merle E ^a   Carpenter, Charles ^b   Klein, Robert S ^c   Rompalo, Ann ^d   Schuman, Paula ^d   Holmberg, Scott D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BROWN UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Cause of death; HIV; Injection drug use; Mortality; Women

Indexed keywords

DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DEATH CERTIFICATE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAUSE OF DEATH; COHORT STUDIES; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 0742323256     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jtg074     Document Type: Article

References (40)

1. Obiri GU, Fordyce EJ, Singh TP, Fortenza S. Effect of HIV/AIDS versus other causes of death on premature mortality in New York City, 1983-1994. Am J Epidemiol. 1998; 147:840-845.
2. Mylonakis E, Koutkia P, Rich JD, et al. Substance abuse is responsible for most pre-AIDS deaths among women with HIV infection in Providence, Rhode Island, USA. AIDS. 1998;12:958-959.
3. Petry NM, Bickel WK, Badger GJ. A 12-year study (1975-1986) of mortality in methadone-maintenance patients: selected demographic characteristics and drug-use patterns of AIDS and non-AIDS-related deaths. Subst Use Misuse. 1998;33:2521-2534.
4. Vlahov D, Munoz A, Solomon L, et al. HIV related mortality in a cohort of injecting drug users [Abstr 257]. Program and Abstracts of The First National Conference on Human Retroviruses and Related Infections; December 12-16, 1993; Washington DC.
5. Poole WK, Fulkerson W, Lou Y, et al. Overall and cause-specific mortality in a cohort of homo-/bisexual men, injecting drug users, and female partners of HIV-infected men. AIDS. 1996;10:1257-1264.
6. Zaccarelli M, Gattari P, Rezza G, et al. Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS. 1994;8:345-350.
7. Perucci CA, Forastiere F, Rapiti E, et al. The impact of intravenous drug use on mortality of young adults in Rome, Italy. Br J Addict. 1992;87:1637-1641.
8. Galli M, Musicco M, the COMCAT Study Group. Mortality of intravenous drug users living in Milan, Italy: role of HIV-1 infection. AIDS. 1994;8:1457-1463.
9. Prins M, Aguado IH, Brettle RP, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS. 1997;11:1747-1756.
10. Mezzelani P, Quaglio GL, Venturini L, et al. A multicentre study on the causes of death among Italian injecting drug users: AIDS has overtaken overdose as the principal cause of death. AIDS Care. 1998;10:61-67.
11. Laurichesse HAA, Mortimer J, Evans BG, Farrington CP. Pre-AIDS mortality in HIV-infected individuals in England, Wales, and Northern Ireland, 1982-1996. AIDS. 1998; 12:651-655.
12. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998; 280:1497-1503.
13. Palella FJ, Delaney KM, Moorman AC, et al. Declining mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med. 1998;338:853-886.
14. Palacio H, Kahn JG, Richards TA, Morun SF. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002;1117:233-251.
15. Laine C, Hauck W, Turner B. Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users. Med Care. 2002;40:976-995.
16. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544-546.
17. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999;21:114-119.
18. Turner BJ, Zhang D, Laine C, Pomerantz RJ, Cosler L, Hauck WW. Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. J Acquir Immune Defic Syndr. 2001;27:20-29.
19. Smith DK, Warren DL, Vlahov D, et al. Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol. 1997;146:459-469.
20. Solomon L, Stein M, Flynn C, et al. Health services use by urban women with or at risk for HIV-1 infection: the HIV Epidemiology Research Study (HERS). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:253-261.
21. Thomas DL, Rich J, Schuman P, et al. Multicenter evaluation of hepatitis C RNA levels among female injecting drug users. J Infect Dis. 2001;183:973-976.
22. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:(RR-17), 1-19.
23. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
24. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16:2175-2182.
25. Tarwater PM, Mellors J, Gore ME, et al. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol. 2001;154:675-681.
26. Wolfe MI, Hanson DL, Selik R, Swerdlow DL. Deaths from non-AIDS related diseases have increased as a proportion of deaths of HIV-infected persons since the advent of HAART [abstr 14]. In: Progam and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, WA.
27. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
28. Vandentorren S, Mercie P, Marimoutou C, et al. Trends in causes of death in the Acquitaine cohort of HIV-infected patients, 1995-1997. Eur J Epidemiol. 2001;17:7-10.
29. Valdez H, Chowdhry TK, Assad R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis. 2001;32:1487-1493.
30. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis. 2001;33:1793-1794.
31. Mocroft A, Brettle O, Kirk A, Blaxhult JM, et al. Changes in cause of death across Europe [abstr 298]. In: Program and Abstracts of the 8th Conference of Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, IL.
32. Cohen M, French A, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002;113:91-98.
33. Rabkin CS, Biggar RJ, Baptiste MS, et al. Cancer incidence trends in women at high risk of human immunodeficiency virus (HIV) infection. Int J Cancer. 1993;55:208-212.
34. Duerr A, Kieke B, Warren D, et al. Human papillomavirus (HPV) associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. Am J Obstet Gynecol. 2001;84:584-590.
35. Phelps RM, Smith DK, Heilig CM, et al. Cancer incidence in women with or at risk for HIV. Int J Cancer. 2001;94:753-757.
36. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in cause of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco. J Infect Dis. 2002;186:1023-1027.
37. Cina SJ, Selby DM, Clak B. Accuracy of death certification in two tertiary care military hospitals. Military Med. 1999;164:897-899.
38. Lu TH, Shau WY, Shih TP, Lee MC, Chou MC, Lin CK. Factors associated with errors in death certificate completion. J Clin Epidemiol. 2001;54:232-238.
39. Johansson LA, Westerling R. Comparing hospital records with death certificates: can the differences be explained? J Epidemiol Community Health. 2002;56:301-308.
40. Messite J, Stellman S. Accuracy of death certificate completion: the need for formalized physician training. JAMA. 1996;275:794-796.